Search Results - "Newell, D.R."

325 Identification and characterization of an irreversible inhibitor of CDK2 by Martin, M, Anscombe, E, Meschini, E, Staunton, D, Geitmann, M, Danielson, U.H, Wang, L.Z, Vidal, R. Mora, Reuillon, T, Golding, B.T, Newell, D.R, Wedge, S, Noble, M.E.M, Endicott, J.A, Griffin, R.J

Get full text

276 An X-ray crystal structure-based understanding of the inhibition of the MDM2–p53 protein–protein interaction by isoindolinones by Anil, B, Blackburn, E, Blackburn, T, Cully, S, Liu, J, Drummond, C.J, Endicott, J.A, Golding, B.T, Griffin, R.J, Haggerty, K, Lunec, J, Newell, D.R, Revill, C.H, Riedinger, C, Watson, A.F, Xu, Q, Zhao, Y, Hardcastle, I.R, Noble, M.E.M

Get full text

35 ORAL Clinical attrition rates for kinase inhibitors in oncology by Walker, I, Newell, D.R

Get full text

60 Pre-clinical evaluation of combinations of PI3K & MEK inhibitors in colorectal carcinoma cell lines by Cox, E.J, Kyle, S, Beale, G.S, Maxwell, R.J, Newell, D.R

Get full text

445 Structure-based design of C8-substituted O6-alkylguanine CDK1 and 2 inhibitors by Carbain, B, Roche, C, Endicott, J.A, Golding, B.T, Hardcastle, I.R, Cano, C, Zhen-Wang, L, Newell, D.R, Noble, M.E.M, Griffin, R.J

Get full text

443 Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK) by Clapham, K.M, Rennison, T, Rodriguez-Aristegui, S, Bardos, J, Curtin, N.J, Golding, B.T, Hardcastle, I.R, Newell, D.R, Cano, C, Griffin, R.J

Get full text

70 POSTER In vitro activity of the multi targeted receptor tyrosine kinase inhibitor sunitinib against multiple myeloma cell lines is not predictive of in vivo xenograft response by Batey, M, Brito, J.L.R, Maitland, H, Leung, H, Hall, A, Jackson, G, Newell, D.R, Irving, J.A.E

Get full text

437 POSTER MDM2 and MDMX status as a determinant of in vitro cellular sensitivity to MDM2 antagonists in human tumour cell lines by Lu, X, Liu, J, Watson, A, Hardcastle, I.R, Griffin, R.J, Golding, B.T, Newell, D.R, Lunec, J

Get full text

Commentary by Lowis, S., Newell, D.R

Get full text

Commentary by Lowis, S., Newell, D.R

Get full text

Inhibition of telomerase activity by cisplatin in human testicular cancer cells by Burger, A.M., Double, J.A., Newell, D.R.

“…Telomerase, a ribonucleoprotein, elongates and/or maintains telomeres by adding TTAGGG tandem repeat sequences using the RNA component of the enzyme as a…”
Get full text

The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies by Newell, D.R., Silvester, J., McDowell, C., Burtles, S.S.

“…Pre-clinical toxicology studies in rodents and Phase I clinical trial data are summarised for 14 novel anticancer therapies. With only one exception, an…”
Get full text

Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) by Batey, M.A., Wright, J.G., Azzabi, A., Newell, D.R., Lind, M.J., Calvert, A.H., Boddy, A.V.

“…Despite the success of adjuvant cyclophosphamide, methotrexate (MTX), 5-fluouracil (5-FU) (CMF) treatment for early stage breast cancer, more than 35% of…”
Get full text

Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines by Cressey, T.R, Tilby, M.J, Newell, D.R

“…Telomere stabilisation is a critical step in tumorigenesis and telomerase, an enzyme which counteracts telomeric DNA loss, is active in most tumours…”
Get full text

Measurement of 5,10-dideaza-5,6,7,8-tetrahydrofolate (lometrexol) in human plasma and urine by high-performance liquid chromatography by Wedge, S.R., Laohavinij, S., Taylor, G.A., Newell, D.R.

“…Three high-performance liquid chromatographic methods are described for the detection of the novel antifolate anticancer drug (6…”
Get full text

The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy by Griffin, R.J., Curtin, N.J., Newell, D.R., Golding, B.T., Durkacz, B.W., Calvert, A.H.

“…Poly(ADP-ribose) polymerase (PARP) plays an important role in a number of cellular processes including DNA repair. Since poly(ADP-ribosyl)ation occurs in…”
Get full text

478 Preclinical investigation of novel inhibitors of DNA dependent protein kinase by Batey, M.A., Zhao, Y., Thomas, H.D., Smith, G.C.M., Newell, D.R., Curtin, N.J.

Get full text

Cisplatin pharmacokinetics in children with cancer by Peng, B., English, M.W., Boddy, A.V., Price, L., Wyllie, R., Pearson, A.D.J., Tilby, M.J., Newell, D.R.

“…Cisplatin is an important drug in the treatment of a number of paediatric cancers yet, despite wide-spread use, there are only very limited data on the…”
Get full text

Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels by Ghazal-Aswad, S., Tilby, M.J., Lind, M., Baily, N., Sinha, D. P., Calvert, A. H., Newell, D. R.

“…Background: Platinum based drugs are active agents in epithelial ovarian cancer and increased platinum drug dose intensity is thought to lead to improved…”
Get full text

Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients by Peng, B., Boddy, A.V., Cole, M., Pearson, A.D.J., Chatelut, E., Rubie, H., Newell, D.R.

“…The antitumour and toxic effects of platinum drugs, in particular carboplatin, have been related to their plasma concentration and this has led to the concept…”
Get full text